Literature DB >> 21493797

Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

Mukta Arora1, John P Klein, Daniel J Weisdorf, Anna Hassebroek, Mary E D Flowers, Corey S Cutler, Alvaro Urbano-Ispizua, Joseph H Antin, Brian J Bolwell, Michael Boyiadzis, Jean-Yves Cahn, Mitchell S Cairo, Luis Isola, David A Jacobsohn, Madan Jagasia, Thomas R Klumpp, Stephanie J Lee, Effie W Petersdorf, Stella Santarone, Robert Peter Gale, Harry C Schouten, Stephen Spellman, John R Wingard, Mary M Horowitz, Steven Z Pavletic.   

Abstract

Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.

Entities:  

Mesh:

Year:  2011        PMID: 21493797      PMCID: PMC3123030          DOI: 10.1182/blood-2010-12-323824

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.

Authors:  Gorgun Akpek; Stephanie J Lee; Mary E Flowers; Steven Z Pavletic; Mukta Arora; Shing Lee; Steven Piantadosi; Katherine A Guthrie; James C Lynch; Alessandra Takatu; Mary M Horowitz; Joseph H Antin; Daniel J Weisdorf; Paul J Martin; Georgia B Vogelsang
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

2.  IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade.

Authors:  P A Rowlings; D Przepiorka; J P Klein; R P Gale; J R Passweg; P J Henslee-Downey; J Y Cahn; S Calderwood; A Gratwohl; G Socié; M M Abecasis; K A Sobocinski; M J Zhang; M M Horowitz
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

3.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.

Authors:  K M Sullivan; R P Witherspoon; R Storb; P Weiden; N Flournoy; S Dahlberg; H J Deeg; J E Sanders; K C Doney; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

4.  Development of a prognostic model for grading chronic graft-versus-host disease.

Authors:  G Akpek; M L Zahurak; S Piantadosi; J Margolis; J Doherty; R Davidson; G B Vogelsang
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

5.  Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.

Authors:  Paul J Martin; Barry E Storer; Paul A Carpenter; Daniel R Couriel; Mary E D Flowers; Vikas Gupta; Jack W Hsu; Madan Jagasia; Carrie L Kitko; Richard T Maziarz; Scott D Rowley; Paul J Shaughnessy; Koen van Besien; Daniel Weisdorf; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-30       Impact factor: 5.742

6.  Chronic graft-versus-host disease: a prospective cohort study.

Authors:  Mukta Arora; Linda J Burns; Stella M Davies; Margaret L Macmillan; Todd E Defor; Wesley J Miller; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-01       Impact factor: 5.742

7.  Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.

Authors:  J R Wingard; S Piantadosi; G B Vogelsang; E R Farmer; D A Jabs; L S Levin; W E Beschorner; R A Cahill; D F Miller; D Harrison
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

8.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.

Authors:  Afonso C Vigorito; Paulo V Campregher; Barry E Storer; Paul A Carpenter; Carina K Moravec; Hans-Peter Kiem; Matthew L Fero; Edus H Warren; Stephanie J Lee; Frederick R Appelbaum; Paul J Martin; Mary E D Flowers
Journal:  Blood       Date:  2009-05-21       Impact factor: 22.113

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  52 in total

1.  Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  M Y Detrait; S Morisset; R Peffault de Latour; I Yakoub-Agha; R Crocchiolo; R Tabrizi; J-O Bay; P Chevalier; F Barraco; N Raus; S Vigouroux; L Magro; M Mohty; N Milpied; D Blaise; G Socié; M Michallet
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.

Authors:  David A Jacobsohn; Brenda F Kurland; Joseph Pidala; Yoshihiro Inamoto; Xiaoyu Chai; Jeanne M Palmer; Sally Arai; Mukta Arora; Madan Jagasia; Corey Cutler; Daniel Weisdorf; Paul J Martin; Steven Z Pavletic; Georgia Vogelsang; Stephanie J Lee; Mary E D Flowers
Journal:  Blood       Date:  2012-07-06       Impact factor: 22.113

3.  Assessment of joint and fascia manifestations in chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Joseph Pidala; Xiaoyu Chai; Brenda F Kurland; Daniel Weisdorf; Mary E D Flowers; Jeanne Palmer; Sally Arai; David Jacobsohn; Corey Cutler; Madan Jagasia; Jenna D Goldberg; Paul J Martin; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee; Paul A Carpenter
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

4.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

5.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

6.  Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

7.  Evaluation of prognostic factors among patients with chronic graft-versus-host disease.

Authors:  Jose A Pérez-Simón; Gabriel Afram; Rodrigo Martino; Jose L Piñana; Teresa Caballero-Velazquez; Olle Ringden; David Valcarcel; Dolores Caballero; Mats Remberger; Yanira de Paz; Jordi Sierra; Jesús San Miguel; Hans Hagglund
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

Review 8.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

9.  Providing personalized prognostic information for adult leukemia survivors.

Authors:  Stephanie J Lee; Barry Storer; Hailin Wang; Hillard M Lazarus; Edmund K Waller; Luis M Isola; Thomas R Klumpp; John Bosco C Umejiego; Bipin N Savani; Alison W Loren; Mitchell S Cairo; Bruce M Camitta; Corey S Cutler; Biju George; H Jean Khoury; David I Marks; David A Rizzieri; Edward A Copelan; Vikas Gupta; Jane L Liesveld; Mark R Litzow; Alan M Miller; Harry C Schouten; Robert Peter Gale; Jean-Yves Cahn; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-06       Impact factor: 5.742

10.  Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Paul J Martin; Barry E Storer; Jeanne Palmer; Daniel J Weisdorf; Joseph Pidala; Mary E D Flowers; Mukta Arora; Madan Jagasia; Sally Arai; Xiaoyu Chai; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.